Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Review

Pyroptosis at the forefront of anticancer immunity

Authors: Reid Loveless, Ryan Bloomquist, Yong Teng

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Tumor resistance to apoptosis and the immunosuppressive tumor microenvironment are two major contributors to poor therapeutic responses during cancer intervention. Pyroptosis, a lytic and inflammatory programmed cell death pathway distinct from apoptosis, has subsequently sparked notable interest among cancer researchers for its potential to be clinically harnessed and to address these problems. Recent evidence indicates that pyroptosis induction in tumor cells leads to a robust inflammatory response and marked tumor regression. Underlying its antitumor effect, pyroptosis is mediated by pore-forming gasdermin proteins that facilitate immune cell activation and infiltration through their release of pro-inflammatory cytokines and immunogenic material following cell rupture. Considering its inflammatory nature, however, aberrant pyroptosis may also be implicated in the formation of a tumor supportive microenvironment, as evidenced by the upregulation of gasdermin proteins in certain cancers. In this review, the molecular pathways leading to pyroptosis are introduced, followed by an overview of the seemingly entangled links between pyroptosis and cancer. We describe what is known regarding the impact of pyroptosis on anticancer immunity and give insight into the potential of harnessing pyroptosis as a tool and applying it to novel or existing anticancer strategies.

Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30(1):1–14.CrossRef

Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020;121:109595. https://doi.org/10.1016/j.biopha.2019.109595.CrossRefPubMed

de Vasconcelos NM, Lamkanfi M. Recent insights on inflammasomes, gasdermin pores, and pyroptosis. Cold Spring Harb Perspect Biol. 2020;12(5):a036392. https://doi.org/10.1101/cshperspect.a036392.CrossRefPubMed

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):1–17.CrossRef

Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99–103. https://doi.org/10.1038/nature22393.CrossRefPubMed

Bebber CM, Müller F, Prieto Clemente L, Weber J, von Karstedt S. Ferroptosis in cancer cell biology. Cancers. 2020;12(1):164. https://doi.org/10.3390/cancers12010164.CrossRefPubMedCentral

Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12(1):1–16.CrossRef

Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21(1):39–49. https://doi.org/10.1038/cdd.2013.84.CrossRefPubMed

Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. https://doi.org/10.3389/fimmu.2018.02379.CrossRefPubMedPubMedCentral

10.

Tang R, Xu J, Zhang B, Liu J, Liang C, Hua J, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):1–18.CrossRef

11.

Monack DM, Raupach B, Hromockyj AE, Falkow S. Salmonella typhimurium invasion induces apoptosis in infected macrophages. Proc Natl Acad Sci. 1996;93(18):9833–8. https://doi.org/10.1073/pnas.93.18.9833.CrossRefPubMedPubMedCentral

12.

Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature. 1992;358(6382):167–9. https://doi.org/10.1038/358167a0.CrossRefPubMed

13.

Hilbi H, Moss JE, Hersh D, Chen Y, Arondel J, Banerjee S, et al. Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J Biol Chem. 1998;273(49):32895–900. https://doi.org/10.1074/jbc.273.49.32895.CrossRefPubMed

14.

Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8(11):1812–25. https://doi.org/10.1111/j.1462-5822.2006.00751.x.CrossRefPubMed

15.

Wu C, Lu W, Zhang Y, Zhang G, Shi X, Hisada Y, et al. Inflammasome activation triggers blood clotting and host death through pyroptosis. Immunity. 2019;50(6):1401–11. e1404.

16.

Zhaolin Z, Guohua L, Shiyuan W, Zuo W. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019;52(2):e12563. https://doi.org/10.1111/cpr.12563.CrossRefPubMed

17.

Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11(6):e10248.CrossRef

18.

Doitsh G, Galloway NL, Geng X, Yang Z, Monroe KM, Zepeda O, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505(7484):509–14. https://doi.org/10.1038/nature12940.CrossRefPubMedPubMedCentral

19.

Qiu Z, Lei S, Zhao B, Wu Y, Su W, Liu M, et al. NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial ischemia/reperfusion injury in diabetic rats. Oxid Med Cell Longev. 2017;2017.

20.

Kuang S, Zheng J, Yang H, Li S, Duan S, Shen Y, et al. Structure insight of GSDMD reveals the basis of GSDMD autoinhibition in cell pyroptosis. Proc Natl Acad Sci. 2017;114(40):10642–7. https://doi.org/10.1073/pnas.1708194114.CrossRefPubMedPubMedCentral

21.

Guey B, Bodnar M, Manié SN, Tardivel A, Petrilli V. Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc Natl Acad Sci. 2014;111(48):17254–9. https://doi.org/10.1073/pnas.1415756111.CrossRefPubMedPubMedCentral

22.

Shi J, Zhao Y, Wang Y, Gao W, Ding J, Li P, et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature. 2014;514(7521):187–92. https://doi.org/10.1038/nature13683.CrossRefPubMed

23.

Nyström S, Antoine DJ, Lundbäck P, Lock JG, Nita AF, Högstrand K, et al. TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J. 2013;32(1):86–99. https://doi.org/10.1038/emboj.2012.328.CrossRefPubMed

24.

Wang K, Sun Q, Zhong X, Zeng M, Zeng H, Shi X, et al. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis. Cell. 2020;180(5):941–55. e920.

25.

Kayagaki N, Warming S, Lamkanfi M, Walle LV, Louie S, Dong J, et al. Non-canonical inflammasome activation targets caspase-11. Nature. 2011;479(7371):117–21. https://doi.org/10.1038/nature10558.CrossRefPubMed

26.

Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling. Nature. 2015;526(7575):666–71. https://doi.org/10.1038/nature15541.CrossRefPubMed

27.

Gao J, Qiu X, Xi G, Liu H, Zhang F, Lv T, et al. Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non-small cell lung cancer. Oncol Rep. 2018;40(4):1971–84. https://doi.org/10.3892/or.2018.6634.CrossRefPubMedPubMedCentral

28.

Tsuchiya K, Nakajima S, Hosojima S, Nguyen DT, Hattori T, Le TM, et al. Caspase-1 initiates apoptosis in the absence of gasdermin D. Nat Commun. 2019;10(1):1–19.CrossRef

29.

Lee BL, Mirrashidi KM, Stowe IB, Kummerfeld SK, Watanabe C, Haley B, et al. ASC-and caspase-8-dependent apoptotic pathway diverges from the NLRC4 inflammasome in macrophages. Sci Rep. 2018;8(1):1–12.

30.

Chen KW, Demarco B, Heilig R, Shkarina K, Boettcher A, Farady CJ, et al. Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP 3 inflammasome assembly. EMBO J. 2019;38(10):e101638.PubMedPubMedCentral

31.

Demarco B, Grayczyk JP, Bjanes E, Le Roy D, Tonnus W, Assenmacher C-A, et al. Caspase-8–dependent gasdermin D cleavage promotes antimicrobial defense but confers susceptibility to TNF-induced lethality. Sci Adv. 2020;6(47):eabc3465.

32.

Aizawa E, Karasawa T, Watanabe S, Komada T, Kimura H, Kamata R, et al. GSDME-dependent incomplete pyroptosis permits selective IL-1α release under caspase-1 inhibition. iScience. 2020;23(5):101070.

33.

Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–20. https://doi.org/10.1038/s41586-020-2071-9.CrossRefPubMedPubMedCentral

34.

Li L, Li Y, Bai Y. Role of GSDMB in Pyroptosis and Cancer. Cancer Manag Res. 2020;12:3033–43. https://doi.org/10.2147/CMAR.S246948.CrossRefPubMedPubMedCentral

35.

Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020;368(6494).

36.

Hou J, Zhao R, Xia W, Chang C-W, You Y, Hsu J-M, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264–75. https://doi.org/10.1038/s41556-020-0575-z.CrossRefPubMedPubMedCentral

37.

Tang L, Lu C, Zheng G, Burgering BM. Emerging insights on the role of gasdermins in infection and inflammatory diseases. Clin Transl Immunol. 2020;9(10):e1186.CrossRef

38.

Wang M, Jiang S, Zhang Y, Li P, Wang K. The multifaceted roles of pyroptotic cell death pathways in cancer. Cancers. 2019;11(9):1313. https://doi.org/10.3390/cancers11091313.CrossRefPubMedCentral

39.

Tan G, Huang C, Chen J, Zhi F. HMGB1 released from GSDME-mediated pyroptotic epithelial cells participates in the tumorigenesis of colitis-associated colorectal cancer through the ERK1/2 pathway. J Hematol Oncol. 2020;13(1):1–11.CrossRef

40.

Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4(8):641–8. https://doi.org/10.1038/nri1415.CrossRefPubMed

41.

Wang F, Liu W, Ning J, Wang J, Lang Y, Jin X, et al. Simvastatin suppresses proliferation and migration in non-small cell lung cancer via pyroptosis. Int J Biol Sci. 2018;14(4):406–17. https://doi.org/10.7150/ijbs.23542.CrossRefPubMedPubMedCentral

42.

C-c Z, C-g L, Wang Y-f, Xu L-h, He X-h, Q-z Z, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation. Apoptosis. 2019;24(3):312–25.

43.

Lu H, Zhang S, Wu J, Chen M, Cai M-C, Fu Y, et al. Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death. Clin Cancer Res. 2018;24(23):6066–77. https://doi.org/10.1158/1078-0432.CCR-18-1478.CrossRefPubMed

44.

Zhang Y, Yang H, Sun M, He T, Liu Y, Yang X, et al. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis. Pharmacol Rep. 2020;72(5):1370–82. https://doi.org/10.1007/s43440-020-00064-8.CrossRefPubMed

45.

Chu Q, Jiang Y, Zhang W, Xu C, Du W, Tuguzbaeva G, et al. Pyroptosis is involved in the pathogenesis of human hepatocellular carcinoma. Oncotarget. 2016;7(51):84658–65. https://doi.org/10.18632/oncotarget.12384.CrossRefPubMedPubMedCentral

46.

Hergueta-Redondo M, Sarrió D, Molina-Crespo Á, Megias D, Mota A, Rojo-Sebastian A, et al. Gasdermin-B promotes invasion and metastasis in breast cancer cells. PLoS One. 2014;9(3):e90099. https://doi.org/10.1371/journal.pone.0090099.CrossRefPubMedPubMedCentral

47.

Kim MS, Lebron C, Nagpal JK, Chae YK, Chang X, Huang Y, et al. Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochem Biophys Res Commun. 2008;370(1):38–43. https://doi.org/10.1016/j.bbrc.2008.03.026.CrossRefPubMedPubMedCentral

48.

Sun Y, Guo Y. Expression of Caspase-1 in breast cancer tissues and its effects on cell proliferation, apoptosis and invasion. Oncol Lett. 2018;15(5):6431–5. https://doi.org/10.3892/ol.2018.8176.CrossRefPubMedPubMedCentral

49.

Wei Y, Huang H, Qiu Z, Li H, Tan J, Ren G, et al. NLRP1 overexpression is correlated with the tumorigenesis and proliferation of human breast tumor. Biomed Res Int. 2017;2017:1–9. https://doi.org/10.1155/2017/4938473.CrossRef

50.

Miguchi M, Hinoi T, Shimomura M, Adachi T, Saito Y, Niitsu H, et al. Gasdermin C is upregulated by inactivation of transforming growth factor β receptor type II in the presence of mutated Apc, promoting colorectal cancer proliferation. PLoS One. 2016;11(11):e0166422. https://doi.org/10.1371/journal.pone.0166422.CrossRefPubMedPubMedCentral

51.

Kim M, Chang X, Yamashita K, Nagpal J, Baek J, Wu G, et al. Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma. Oncogene. 2008;27(25):3624–34. https://doi.org/10.1038/sj.onc.1211021.CrossRefPubMed

52.

Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, et al. Lack of absent in melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int J Cancer. 2014;135(10):2387–96. https://doi.org/10.1002/ijc.28891.CrossRefPubMed

53.

Hu B, Elinav E, Huber S, Booth CJ, Strowig T, Jin C, et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci. 2010;107(50):21635–40. https://doi.org/10.1073/pnas.1016814108.CrossRefPubMedPubMedCentral

54.

Chen C, Wang B, Sun J, Na H, Chen Z, Zhu Z, et al. DAC can restore expression of NALP1 to suppress tumor growth in colon cancer. Cell Death Dis. 2015;6(1):e1602–2. https://doi.org/10.1038/cddis.2014.532.

55.

Saeki N, Kim D, Usui T, Aoyagi K, Tatsuta T, Aoki K, et al. GASDERMIN, suppressed frequently in gastric cancer, is a target of LMO1 in TGF-β-dependent apoptotic signalling. Oncogene. 2007;26(45):6488–98. https://doi.org/10.1038/sj.onc.1210475.CrossRefPubMed

56.

Saeki N, Usui T, Aoyagi K, Kim DH, Sato M, Mabuchi T, et al. Distinctive expression and function of four GSDM family genes (GSDMA-D) in normal and malignant upper gastrointestinal epithelium. Genes Chromosom Cancer. 2009;48(3):261–71. https://doi.org/10.1002/gcc.20636.CrossRefPubMed

57.

Wang WJ, Chen D, Jiang MZ, Xu B, Li XW, Chu Y, et al. Downregulation of gasdermin D promotes gastric cancer proliferation by regulating cell cycle-related proteins. J Dig Dis. 2018;19(2):74–83. https://doi.org/10.1111/1751-2980.12576.CrossRefPubMed

58.

Akino K, Toyota M, Suzuki H, Imai T, Maruyama R, Kusano M, et al. Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. Cancer Sci. 2007;98(1):88–95. https://doi.org/10.1111/j.1349-7006.2006.00351.x.CrossRefPubMed

59.

Croes L, Fransen E, Hylebos M, Buys K, Hermans C, Broeckx G, et al. Determination of the potential tumor-suppressive effects of GSDME in a chemically induced and in a genetically modified intestinal cancer mouse model. Cancers. 2019;11(8):1214.CrossRef

60.

Jiang Z, Yao L, Ma H, Xu P, Li Z, Guo M, et al. miRNA-214 inhibits cellular proliferation and migration in glioma cells targeting caspase 1 involved in pyroptosis. Oncol Res. 2017;25(6):1009–19. https://doi.org/10.3727/096504016X14813859905646.CrossRefPubMedPubMedCentral

61.

Ma X, Guo P, Qiu Y, Mu K, Zhu L, Zhao W, et al. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway. Oncotarget. 2016;7(24):36185–97. https://doi.org/10.18632/oncotarget.9154.CrossRefPubMedPubMedCentral

62.

Zhai Z, Samson JM, Yamauchi T, Vaddi PK, Matsumoto Y, Dinarello CA, et al. Inflammasome sensor NLRP1 confers acquired drug resistance to temozolomide in human melanoma. Cancers. 2020;12(9):2518. https://doi.org/10.3390/cancers12092518.CrossRefPubMedCentral

63.

Zhai Z, Liu W, Kaur M, Luo Y, Domenico J, Samson JM, et al. NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene. 2017;36(27):3820–30. https://doi.org/10.1038/onc.2017.26.CrossRefPubMedPubMedCentral

64.

Winter RN, Kramer A, Borkowski A, Kyprianou N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 2001;61(3):1227–32.PubMed

65.

Wang M, Chen X, Zhang Y. Biological functions of Gasdermins in Cancer: from molecular mechanisms to therapeutic potential. Front Cell Dev Biol. 2021;9:189.

66.

Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Tar. 2021;6(1):1–21.CrossRef

67.

Ibrahim J. Op de Beeck K, Fransen E, Croes L, Beyens M, Suls a, Vanden Berghe W, Peeters M, Van camp G. methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer. Cancer Med. 2019;8(5):2133–45. https://doi.org/10.1002/cam4.2103.CrossRefPubMedPubMedCentral

68.

Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40(1):1–15.CrossRef

69.

Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 2020;11(11):1–13, 1013. https://doi.org/10.1038/s41419-020-03221-2.

70.

Wang Q, Wang Y, Ding J, Wang C, Zhou X, Gao W, et al. A bioorthogonal system reveals antitumour immune function of pyroptosis. Nature. 2020;579(7799):421–6. https://doi.org/10.1038/s41586-020-2079-1.CrossRefPubMed

71.

Xi G, Gao J, Wan B, Zhan P, Xu W, Lv T, et al. GSDMD is required for effector CD8+ T cell responses to lung cancer cells. Int Immunopharmacol. 2019;74:105713. https://doi.org/10.1016/j.intimp.2019.105713.CrossRefPubMed

72.

Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43).

73.

Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10(2):254–69. https://doi.org/10.1158/2159-8290.CD-19-0672.CrossRefPubMed

74.

Gao Y, Zhang H, Zhou N, Xu P, Wang J, Gao Y, et al. Methotrexate-loaded tumour-cell-derived microvesicles can relieve biliary obstruction in patients with extrahepatic cholangiocarcinoma. Nat Biomed Eng. 2020;4(7):743–53. https://doi.org/10.1038/s41551-020-0583-0.CrossRefPubMed

75.

Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDME-mediated cancer cell pyroptosis. Cell Cycle. 2020;19(10):1089–104. https://doi.org/10.1080/15384101.2020.1743911.CrossRefPubMedPubMedCentral

76.

Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, et al. Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res. 2018;78(21):6183–95. https://doi.org/10.1158/0008-5472.CAN-18-0730.CrossRefPubMed

77.

Chen L, Li Q, Zheng Z, Xie J, Lin X, Jiang C, et al. Design and optimize N-substituted EF 24 as effective and low toxicity NF-κB inhibitor for lung cancer therapy via apoptosis-to-pyroptosis switch. Chem Biol Drug Des. 2019;94(1):1368–77. https://doi.org/10.1111/cbdd.13514.CrossRefPubMed

78.

Chen L, Weng B, Li H, Wang H, Li Q, Wei X, et al. A thiopyran derivative with low murine toxicity with therapeutic potential on lung cancer acting through a NF-κB mediated apoptosis-to-pyroptosis switch. Apoptosis. 2019;24(1):74–82. https://doi.org/10.1007/s10495-018-1499-y.CrossRefPubMed

79.

Fan J-X, Deng R-H, Wang H, Liu X-H, Wang X-N, Qin R, et al. Epigenetics-based tumor cells pyroptosis for enhancing the immunological effect of chemotherapeutic nanocarriers. Nano Lett. 2019;19(11):8049–58. https://doi.org/10.1021/acs.nanolett.9b03245.CrossRefPubMed

80.

Lu C, Guo C, Chen H, Zhang H, Zhi L, Lv T, et al. A novel chimeric PD1-NKG2D-41BB receptor enhances antitumor activity of NK92 cells against human lung cancer H1299 cells by triggering pyroptosis. Mol Immunol. 2020;122:200–6. https://doi.org/10.1016/j.molimm.2020.04.016.CrossRefPubMed

Title: Pyroptosis at the forefront of anticancer immunity
Authors: Reid Loveless
Ryan Bloomquist
Yong Teng
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02065-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth

Correction to: Hsa_circ_0005273 facilitates breast cancer tumorigenesis by regulating YAP1-hippo signaling pathway

ZBTB28 induces autophagy by regulation of FIP200 and Bcl-XL facilitating cervical cancer cell apoptosis

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis

Long non‐coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer

CircFAM73A promotes the cancer stem cell-like properties of gastric cancer through the miR-490-3p/HMGA2 positive feedback loop and HNRNPK-mediated β-catenin stabilization

Keynote webinar | Spotlight on antibody–drug conjugates in cancer